Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
EXEL
#757
Exelixis, Inc. - Common Stock
55.2
6
USD
-0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.50%
Monthly Change
-2.11%
6 month change
+31.57%
Year Change
+41.55%
Previous Close
56.1
0
Open
55.2
6
Low
55.2
6
High
55.2
6
Volume
182
Markets
US Stock Market
Healthcare
Biotechnology
EXEL
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
Q1, 25
Q2, 25
Current
Key stats
Total common shares outstanding
251.36 M
247.78 M
247.78 M
Valuation ratios
Enterprise value
10.83 B
13.48 B
13.05 B
Price to earnings ratio
14.56
17.41
16.87
Price to sales ratio
5.14
6.19
6
Price to cash flow ratio
13.17
12.76
12.36
Price to book ratio
1.47
1.87
1.81
Enterprise value to EBITDA ratio
11.22
13.48
13.06
Profitability ratios
Return on assets %
0.08
0.09
0.09
Return on equity %
0.11
0.12
0.12
Return on invested capital %
45.96
48.66
48.66
Gross margin %
96.73
96.71
96.71
Operating margin %
41.15
39.51
39.51
EBITDA margin %
42.29
40.62
40.62
Net margin %
34.46
33.73
33.73
Liquidity ratios
Quick ratio
3.19
3.38
3.38
Current ratio
3.26
3.46
3.46
Inventory turnover
0.83
0.75
0.75
Asset turnover
0.22
0.25
0.25
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
0.94
1.19
4.35
EBIT per share
0.94
0.96
3.58
EBITDA per share
0.97
0.98
3.68
Total debt per share
—
—
—
Cash per share
2.91
3.23
3.23
Net current asset value per share
4.52
4.82
4.82
Tangible book value per share
7
6.86
6.86
Working capital per share
3.13
3.42
3.42
Book value per share
7.24
7.1
7.1
News
Tracking Renaissance Technologies (RenTec) 13F Portfolio – Q2 2026 Update
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Here's Why Exelixis (EXEL) is a Strong Value Stock
IHF: Healthcare Dashboard For August (NYSEARCA:IHF)
Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk Are Key Earnings Movers: Weekly Review
Nvidia In Buy Zone, Leads 24 Newbies Onto Best Stock Lists
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript
Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Exelixis (EXEL) Tops Q2 Earnings Estimates
Why This Top-Ranked IBD 50 Stock Just Plummeted On Its Earnings